Cecile Gstalder

Cecile Gstalder is a Senior Scientist at Ridgeline Discovery since October 2022, with previous experience as a Scientist II at FogPharma from July 2021 to August 2022 and as a Postdoctoral Research Fellow at Dana-Farber Cancer Institute from February 2016 to October 2020, where tumor-intrinsic mechanisms of resistance to checkpoint blockade were characterized to inform combination therapies in immunotherapy. Prior to that, Cecile Gstalder completed a PhD at CNRS from October 2011 to September 2015, focusing on sphingolipid metabolism and its implications for renal cell carcinoma. Cecile Gstalder holds a PharmD and multiple degrees in cancer research and biotechnology from Université Paul Sabatier Toulouse III and the University of Strasbourg.